A real world study analysing drug-drug interactions in Italian patients with Chronic Hepatitis C treated with Pangenotypic Direct Acting Agents
Latest Information Update: 29 Jan 2021
Price :
$35 *
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary) ; Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 29 Jan 2021 New trial record